New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
06:20 EDTBCRXBioCryst BSAV BCX4430 highly effective agaist yellow fever in preclinical model
BioCryst Pharmaceuticals announced proof-of-principle data demonstrating that BCX4430 is efficacious and well tolerated in a preclinical disease model for evaluating efficacy against yellow fever virus infection. BCX4430 is the lead compound in BioCryst's broad-spectrum antiviral, or BSAV, research program. The objective of BioCryst's BSAV program is to develop broad-spectrum parenteral and oral therapeutics for viruses that pose a threat to national health and security.
News For BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
13:43 EDTBCRXUSDA says bird flu found in backyard poultry in Oregon
The United States Department of Agriculture’s Animal and Plant Health Inspection Service confirmed the presence of highly pathogenic H5N8 avian influenza in guinea fowl and chickens from a small backyard poultry flock in Winston, Oregon. The H5N8 virus has not been found in commercial poultry anywhere in the United States and there is no immediate public health concern, as the H5N8 virus has been found in birds in other parts of the world and has not caused any human infection to date, the USDA stated. The Fly notes companies that offer or are developing flu vaccines include BioCryst (BCRX) and Novavax (NVAX). Publicly traded meat producers include Hormel Foods (HRL), Pilgrim's Pride (PPC), Sanderson Farms (SAFM) and Tyson Foods (TSN). Reference Link
December 18, 2014
07:21 EDTBCRXBioCryst initiates OPuS-2 clinical trial of BCX4161
Subscribe for More Information
December 15, 2014
07:17 EDTBCRXBioCryst initiates Phase 1 clinical trial of BCX4430
BioCryst Pharmaceuticals announced the dosing of the first subject in a randomized, placebo-controlled Phase 1 clinical trial to evaluate intramuscular, or I.M., administration of BCX4430 in healthy volunteers. BCX4430 is being developed as a potential treatment for hemorrhagic fever viruses, including Ebola virus and Marburg virus disease. The main goals of this first-in-human study are to evaluate the safety, tolerability and pharmacokinetics of escalating doses of BCX4430 administered via I.M. injection in healthy subjects. In part one of the study, subjects will receive a single dose of BCX4430; in part two of the study, subjects will receive BCX4430 for seven days. Up to six single-dose cohorts and four multiple-dose cohorts will be evaluated, with a total of up to 88 volunteers participating.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use